Denosumab reduces secondary fragility fracture risk in osteoporotic women .
Treatment with denosumab reduces secondary fracture risk in women with postmenopausal osteoporosis
Climacteric. 2015 Jun 1:1-237808 osteoperotic women part of the FREEDOM study, were analyzed in this post-hoc analysis. The purpose of this study was to determine how efficacious denosumab (60mg for 36 months) was in preventing fragility fractures and secondary fragility fractures as compared to a placebo. Results indicated that prior fragility fracture was present in 45% of the population, and denosumab treatment significantly reduced the risk of fragility fracture and secondary fragility fracture regardless of subgroup.
Unlock the Full ACE Report
You have access to 4 more FREE articles this month.
Click below to unlock and view this ACE Reports
Unlock Now
Critical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidencecontent for as little as $1.99 per week.
Already have an account? Log in
0 of 4 monthly FREE articles unlocked
